Vigabatrin for childhood partial-onset epilepsies

Area of Science:

• Pediatric Neurology
• Epileptology
• Ophthalmology

Background:

• Vigabatrin is an antiepileptic drug used in pediatric epilepsy.
• Concerns exist regarding potential visual impairment associated with vigabatrin therapy.
• Effectiveness and visual safety data in pediatric populations require further investigation.

Purpose of the Study:

• To assess the effectiveness of vigabatrin in treating pediatric epilepsy.
• To determine the prevalence of symptomatic visual impairment in children receiving vigabatrin.
• To evaluate the long-term safety and efficacy of vigabatrin in a pediatric cohort.

Main Methods:

• Retrospective review of medical records for 156 pediatric epilepsy patients treated with vigabatrin (1998-2010).
• Efficacy assessed using a 5-point scale comparing seizure frequency pre- and post-treatment.
• Visual impairment evaluated through serial ophthalmologic assessments in clinically indicated cases.

Main Results:

• Vigabatrin significantly decreased seizure frequency from 3.7 to 1.8 per baseline within 6 months (P < 0.001).
• Efficacy was sustained for up to 5 years and was independent of epilepsy etiology (e.g., tuberous sclerosis complex).
• No cases of clinically relevant vigabatrin-associated visual impairment were identified in the evaluated patients.

Conclusions:

• Vigabatrin is an effective treatment for refractory childhood partial-onset epilepsy.
• The drug demonstrated sustained efficacy over a 5-year period.
• Symptomatic vision loss was not associated with vigabatrin therapy in this pediatric cohort.